register

News & Trends - MedTech & Diagnostics

NSW hospital first to offer cutting-edge technology for atrial fibrillation

Health Industry Hub | May 15, 2023 |

MedTech & Diagnostics News: Hurstville Private Hospital in New South Wales has proudly become the first hospital to introduce a cutting-edge medical technology to transform the treatment of atrial fibrillation (AF), a condition characterised by an irregular heart rhythm that can result in breathlessness, palpitations and fatigue.

With an estimated 500,000 Australians currently grappling with AF, the introduction of Biosense Webster’s combined nGEN/QDOT MICRO technology provides a much-needed breakthrough in surgical treatment options.

Dr Calvin Hsieh, Cardiologist and Electrophysiologist at Hurstville Private Hospital, stated “Atrial Fibrillation is a major health issue in Australia and a leading cause of stroke and and other morbidities/mortalities.”

Some patients with arrythmias are not successful with, or cannot tolerate, drug therapy. Catheter ablation is associated with a significant improvement in patient quality of life, with studies showing improvements of more than 50% compared to drug therapy.

The technology from Biosense Webster, part of Johnson & Johnson MedTech, combines the world’s first very high-power short duration ablation catheter. This state-of-the-art technology significantly reduces the total ablation procedure time without compromising patient safety. This remarkable feature means that patients undergoing the procedure may experience reduced exposure to harmful radiation and require less anaesthesia.

Prior to the launch of the nGEN/QDot system, ablation technologies relied on lower power delivery, resulting in comparatively longer procedures. The improved efficiency offered by this breakthrough technology translates into a host of benefits for patients, including potentially faster recovery times, reduced nursing and facility time, and fewer complications. Moreover, the time saved per procedure could enable hospitals to accommodate more patients and alleviate procedural waiting times, ultimately improving patient access and reducing overall costs.

Dr Hsieh expressed his excitement, stating “Being the first in New South Wales to offer this cutting-edge technology is a remarkable milestone. Our patients can now benefit from a faster recovery and reduced complications, marking an exciting development in the field of cardiology.”

“We are excited to be at the forefront of this innovative treatment,” said Martina Goddard, CEO of Hurstville Private Hospital which is part of the Healthe Care private hospital group.

For more difficult AF cases, a clinical partnership in Australia is offering advanced surgical ablation. Hollywood Private Hospital is a training and education hub in Australasia for the specialist heart procedure Hybrid Catheter Ablation and Surgical Ablation (HyCASA).

The CONVERGE clinical trial found that the hybrid AF procedure had superior effectiveness compared to endocardial catheter ablation alone for the treatment of persistent atrial fibrillation. 

Hearts4Heart CEO, Tanya Hall, said HyCASA provides an important alternative for patients when other therapies have failed.

“These are the patients with the most debilitating levels of Atrial Fibrillation where no other therapy has proven successful. We would like to see more surgeons being trained in HyCASA so that it is accessible for all patients, in all states across Australia,” Ms Hall said.

Cardiovascular disease affects 16.6% of the Australian population, making it the leading cause of death in the country. Furthermore, cardiovascular disease incurs an annual cost of over $5 billion, surpassing all other diseases in terms of economic impact.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Medtronic partners with local researchers in stroke trial

Medtronic partners with local researchers in stroke trial

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: Endovascular thrombectomy has been shown to be more effective in reducing disability than medical therapy alone […]

More


News & Trends - Pharmaceuticals

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Industry Hub | March 1, 2024 |

Pharma News: Mark Butler MP, Federal Minister for Health, and Senator Anne Ruston, Shadow Minister for Health, reflected on the […]

More


News & Trends - Pharmaceuticals

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Health Industry Hub | March 1, 2024 |

Pharma News: Gilead has applied to the Medical Services Advisory Committee (MSAC) for funding of its cutting-edge CAR T-cell therapy, […]

More


News & Trends - MedTech & Diagnostics

Should private insurers face scrutiny for soaring profits while patients foot the bill? MTAA, Private Healthcare Australia

Should private health insurers face scrutiny for soaring profits while patients foot the bill?

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: In a clash of interests, the Medical Technology Association of Australia (MTAA) has once again urged […]

More


This content is copyright protected. Please subscribe to gain access.